Business context and reporting period
Coeptis Therapeutics Holdings, Inc. (Nasdaq: COEP; warrants: COEPW) filed this Form 10-K for the year ended December 31, 2022. The request metadata names Z Squared Inc., but the filing identifies Coeptis Therapeutics Holdings, Inc. as the registrant. On October 28, 2022, Coeptis completed a reverse merger with former SPAC Bull Horn Holdings Corp.; Coeptis was the accounting acquirer, so historical financial results are principally those of Coeptis Therapeutics, Inc.
Coeptis is an early-stage pharmaceutical company focused on developing and partnering on oncology and other therapies. Its leading programs include co-development rights to CD38-GEAR-NK and CD38-Diagnostic with Vy-Gen, and a licensed SNAP-CAR T-cell platform with the University of Pittsburgh. GEAR-NK and SNAP-CAR are preclinical; CD38-Diagnostic is at discovery/preclinical stages. The company had five employees at year-end.
Financial results and liquidity
| Metric | 2022 | 2021 |
|---|---|---|
| Revenue | $0 | $75,000 |
| Operating expenses | $34.20 million | $14.12 million |
| Loss from operations | $34.20 million | $14.05 million |
| Net loss | $37.57 million | $13.45 million |
| Loss per share | $2.63 | $1.23 |
| Cash used in operating activities | $3.88 million | $4.49 million |
Revenue was nil in 2022; the 2021 amount was consulting revenue. Product revenue has not been meaningful. Gross margin is not meaningful with no 2022 sales. Operating expenses rose sharply, mainly due to warrant-related charges and other financing costs. The 2022 net loss also included a $3.39 million loss on debt extinguishment and asset write-downs. Warrants issued for services ($23.73 million) and debt extinguishment ($3.41 million) were substantial noncash operating cash-flow adjustments.
At December 31, 2022, cash was $3.79 million, total current assets $3.94 million, total current liabilities $1.82 million, total assets $7.92 million, and total liabilities $3.11 million. Current liabilities included $1.50 million of notes payable; long-term notes payable were $150,000. The balance sheet also reported a $1.13 million warrant derivative liability. Cash increased by $1.61 million during 2022, supported by $5.49 million of financing cash inflows, including stock issuances; cash from operations remained negative. The filing provides no meaningful operating margin because the business is development-stage and has no sales.
Material changes versus 2021
- Net loss increased to $37.57 million from $13.45 million, while revenue fell to zero from $75,000.
- Operating expenses more than doubled, primarily reflecting warrant expense associated with strategic financing.
- Cash rose from $2.18 million to $3.79 million, despite continued operating cash burn, as financing activities provided $5.49 million.
- The October 2022 reverse merger changed the public-company structure and resulted in Coeptis becoming the operating business and accounting acquirer.
- Coeptis paid off the Vy-Gen promissory notes during 2022; the notes had a zero balance at year-end. The company also licensed SNAP-CAR technology from the University of Pittsburgh.
Outlook, risks and unusual items
Management expects no significant revenue for at least two years and anticipates continued operating losses and negative operating cash flow through at least the end of 2023. The company said available cash was expected to support short-term needs into the fourth quarter of 2023, assuming it did not pursue strategic transactions. Management expects it will need additional equity or debt financing; availability and terms are uncertain. The auditor’s report and the filing state that substantial doubt exists about the company’s ability to continue as a going concern.
- Funding and debt: The company depends on additional capital to sustain operations and advance development. A $1.50 million Purple BioTech convertible note was due in February 2023; the notes disclose that it was in default as of March 2023. The filing’s year-end classification and subsequent status merit attention.
- Nasdaq listing: Nasdaq notified the company in December 2022 that market value of listed securities had been below the $50 million continued-listing threshold. The stated compliance deadline was June 20, 2023.
- Development and commercialization: Product candidates remain early-stage, with no human trials for the described CD38 programs. The filing anticipated in vivo GEAR-NK work in 2023 and human trials in 2024, contingent on progress, financing and regulatory requirements. No assurance is given that these plans will occur.
- Controls and reporting: Management concluded disclosure controls and internal control over financial reporting were ineffective at year-end because of material weaknesses, including inadequate segregation of duties, accounting procedures, close processes and systems integration. Remediation was underway but not complete.
- Other commitments and portfolio: The company committed $716,714 over two years for University of Pittsburgh SNAP-CAR research and will owe maintenance fees, milestones and 3.5% royalties under the license. Development of CPT60621 was deprioritized, and the company was negotiating a potential buyout of its remaining rights.
- Share dilution: The company reported substantial warrant activity and, after year-end, granted options for 1,357,500 shares at an average $1.63 exercise price. Warrants and equity financing may dilute common shareholders.
Most important facts for investors to verify
- Confirm the filing issuer: the supplied filing is for Coeptis Therapeutics Holdings, Inc., not Z Squared Inc.
- Verify the status and settlement terms of the $1.50 million Purple BioTech note disclosed as in default in March 2023.
- Assess actual cash runway, subsequent financing, and whether management’s going-concern plans are sufficient.
- Check Nasdaq listing compliance and the outcome of the June 20, 2023 deadline.
- Track clinical and preclinical progress, spending commitments, and ownership/revenue-share terms for CD38 and SNAP-CAR programs.
- Review remediation of material weaknesses and the potential dilution from outstanding warrants, options and future capital raises.